458-person creatine trial discussed
- BoxLife Magazine on August 5 said vascular surgeon Dr. Lily Johnston reviewed a 458-person creatine trial while discussing methylation, homocysteine and glycine-related claims. - The central figure was 458 participants in a randomized Bangladeshi adult trial that tested whether creatine supplementation could reduce methylation demand and homocysteine. - The underlying trial is published in The Journal of Nutrition, and Johnston’s comments appear in her recent YouTube video.
BoxLife Magazine on August 5 published an article built around Dr. Lily Johnston’s discussion of creatine, methylation and glycine, citing what it described as a 458-person trial. The article said Johnston, a board-certified vascular surgeon, takes 10 grams of creatine a day and reviewed evidence that supplemental creatine might reduce the body’s need to make creatine on its own. That claim matters because endogenous creatine synthesis uses methyl groups and starts with amino-acid precursors including glycine, according to the article and the underlying literature. The key question is not whether creatine helps gym performance — that is already widely discussed — but whether supplementation changes methylation-related biomarkers in humans. ### Which 458-person trial is this referring to? The 458-person study appears to be a randomized, controlled trial in Bangladeshi adults published in *The Journal of Nutrition* under the title “Low-Dose Creatine Supplementation Lowers Plasma Guanidinoacetate, but Not Plasma Homocysteine, in a Double-Blind, Randomized, Placebo-Controlled Trial.” The study hypothesis, as indexed by the journal and ScienceDirect, was that creatine supplementation would downregulate endogenous creatine synthesis, reduce methylation demand, increase S-adenosylmethionine, decrease S-adenosylhomocysteine, and lower total homocysteine. (boxlifemagazine.com) The trial matters because it directly tested a broader health claim now circulating in supplement media: that taking creatine could spare methyl groups and improve homocysteine-related metabolism in real people, not just in biochemical theory. But the published result, as reflected in the title itself, was narrower than some of the commentary around it: plasma guanidinoacetate fell, while plasma homocysteine did not. (jn.nutrition.org) ### What does glycine have to do with creatine? Creatine synthesis begins when arginine and glycine are combined to form guanidinoacetate, which is then methylated to become creatine, according to the BoxLife article and other background literature. That is why commentators sometimes say supplemental creatine may “spare” glycine and methyl donors: if the body makes less of its own creatine, it may use fewer precursor inputs for that pathway. (jn.nutrition.org) The mechanistic argument is older than this week’s coverage. BoxLife said creatine synthesis consumes a large share of the body’s methyl groups, citing research in the *American Journal of Physiology*. A separate physician-written review published in July likewise said the GAMT reaction that converts guanidinoacetate to creatine is a major methylation expense. Those sources support the biochemical rationale, but they do not by themselves prove broad clinical benefits from supplementation. (boxlifemagazine.com) ### Did the trial actually prove a methylation or homocysteine benefit? The strongest verified answer is mixed. The Bangladeshi trial found evidence consistent with reduced endogenous creatine synthesis, reflected in lower plasma guanidinoacetate, but the published record does not support a clean human win on homocysteine from that trial. That distinction is important because homocysteine reduction is often the practical health claim attached to methylation discussions. (boxlifemagazine.com) Other literature points in different directions. A 2025 paper in the *Journal of the International Society of Sports Nutrition* examined high-dose creatine, with or without guanidinoacetic acid, on homocysteine and health markers, while older animal work reported lower homocysteine with creatine feeding. Those findings show the topic is still being studied, but they do not convert the 458-person trial into proof of a broad clinical benefit. (jn.nutrition.org) ### What can be verified about Dr. Lily Johnston’s role? YouTube shows a recent video titled “This Changes How I Think About Creatine” on Johnston’s channel, posted four days before August 6. BoxLife identified Johnston as a board-certified vascular surgeon specializing in cardiometabolic prevention and said her discussion was conducted alongside fitness coach Tom DeLauer. The BoxLife article also said Johnston personally takes 10 grams of creatine daily. (tandfonline.com) The 10-gram figure should be treated as Johnston’s stated regimen, not as a general recommendation. U.S. regulators classify creatine products as dietary supplements, and the FDA says oversight of supplements differs from prescription-drug review. ### So what is the cleanest takeaway from this week’s story? The cleanest verified takeaway is that this week’s coverage revived an existing scientific question rather than unveiling a new peer-reviewed breakthrough. (youtube.com) BoxLife accurately pointed to a real 458-person human trial and a real biochemical rationale involving glycine and methylation, but the published trial result was more limited than the broadest supplement claims imply. (boxlifemagazine.com) The next step for readers is straightforward. The underlying paper is available through *The Journal of Nutrition* and ScienceDirect, and Johnston’s comments are in her recent YouTube video, both of which provide the named participants and primary material behind this week’s discussion. (jn.nutrition.org) (boxlifemagazine.com)